

CONSENSUS CONFERENCE DI-AIH

Tuesday 1 March 2022

20h Join together dinner at the Parador de Nerja (others will join as they arrive at the Hotel)

Wednesday 2 March 2022

Start (CET) Finish (CET) Presenter details

Each talk & session will come up with a consensus line, gaps of knowledge identified and what kind of studies we need to answer these.

Consensus article to be drafted based on the meeting to be published in JHEP

08.30 08.45 Wellcome & Aims

Scientific Programme Committee:

RJ Andrade, GP Aithal, Einar S Björnsson, MI Lucena

G Mieli-Vergani, D Vergani, R Liberal, YS de Boer

SESSION 1 Terminology and case definitions (Drug-Induced Autoimmune hepatitis (DI-AIH) and AIH)

Chairs: Michael Manns, Raul J Andrade

08.45 09.15 **What is in the name and how the cases with the overlap (DI-AIH) have been defined in the literature?**

Michael Manns, Hannover, Germany

Herbert L Bonkosky, North Carolina, USA

09.15 09.30 **How common is AIH, DILI and how often the overlap?**

Ynto de Boer, Amsterdam, the Netherlands

09.30 09.45 **Drugs linked to DI-AIH and phenotypic features**

Einar S. Bjornsson, Reykjavik, Iceland

Mercedes Robles-Diaz, Malaga, Spain

09.45 10.15 **How Clinical Practice Guidelines refer to these conditions?**

Benedetta Terzioli, Bern, Switzerland

Raul J Andrade, Malaga, Spain

CONSENSUS RECOMMENDATIONS

10:15-10:30

10.30 11.00 Coffee break

SESSION 2 How do you diagnose these conditions?

Chairs: Marcial Sebode, Guruprasad P Aithal

- 11.00 11.15 Which tools are useful in arriving at diagnosis? DILI Causality Assessment Method (RUCAM and RECAM)?
Paul Hayashi, North Caroline, USA
- 11.15 11.30 Which tools are useful in arriving at diagnosis? AIH: International AIH criteria and abbreviated forms)
Rodrigo Liberal, Porto, Portugal
- 11.30 11.45 What laboratory tests support the diagnosis?
Alexander Gerbes, Munich, Germany
- 11.45 12.15 Can biopsy findings differentiate AIH from DI-AIH?
Yoh Zen, London, UK
David Kleiner, NIH, Bethesda, USA
- 12.15 12.45 Genetic biomarkers in DILI vs AIH
Christoph Schramm, Hamburg, Germany
Guruprasad P Aithal, Nottingham, UK

CONSENSUS RECOMMENDATIONS

12:45-13:00

13.00 14.30 Lunch

SESSION 3 New Biomarkers

Chairs: Diego Vergani, Naga Chalasani

- 14.30 15.00 Discussion of real clinical cases linking drugs to AIH. Where do we stand? Two cases
Guido Stirnimann, Bern, Switzerland
Sabine Weber, Munich, Germany
- 15.00 15.15 Can new biomarkers distinguish DIAIH from AIH?
Naga Chalasani, Indiana, USA
- 15.15 15.30 Classical autoantibodies profiling
Diego Vergani, London, UK
- 15.30 15.45 Approaches to identify new autoantibodies
Richard Taubert, Hannover, Germany

CONSENSUS RECOMMENDATIONS

15:45 16:00

Coffee will be available in the room

16.00 Adjourn for the Day

16.10 Visit to the Cueva de Nerja

20h Dinner

Thursday 3 March 2022

Session 4 What is the natural history?

Chairs: Michael Heneghan, Gerd Kullak-Ublick

- 09.00 09.15 Can DI-AIH progress to ALF?
Eleonora de Martin, Paris, France
- 09.15 09.30 How do we treat these conditions?
Michael Heneghan, London, UK
Harshad Devarbhavi, Bangalore, India
- 09.30 10.00 What is the role of re-challenge in DI AIH?
Arie Regev, Indiana, USA
- 10.00 10.15 How do we assess DI-AIH in drug development?
Gerd Kullak-Ublick, Zürich, Switzerland

CONSENSUS RECOMMENDATIONS

10:15 10:30

10:30 11:00 Coffee break

Session 5 Summary of consensus reached

Chair: Einar S Björnsson, Anna Licata, Palermo, Italy

- 11:00 11:15 Summary of the consensus reached
Carlota Londoño, Barcelona, Spain
Palak Trivedi, Birmingham, UK
- 11:15 11:45 Discussion

Session 6 What are the remaining questions and how do you answer them?

Chairs: Robert Fontana, Michigan University, USA; Giorgina Mieli-Vergani, London, UK

- 11:45 12:00 Summary of gaps identified and collaborative research to answer them
M^a Isabel Lucena, Malaga, Spain, John Vierling, Texas, USA
- 12:00 12:30 Discussion
- 12:30 14:00 Lunch
- 14:00 15:00 Overview and actions to be followed
Scientific committee
- 15:00 Adjourn for the Day